[Potential of proteinase-activated receptors as a novel target for treatment of pulmonary hypertension].
Katsuya
K
Hirano
D000818:Animals; D055808:Drug Discovery; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D007097:Imines / Q000494:pharmacology / Q000627:therapeutic use; D007783:Lactones / Q000494:pharmacology / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D011651:Pulmonary Artery; D011652:Pulmonary Circulation / Q000187:drug effects / Q000235:genetics; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D044463:Receptor, PAR-1 / Q000502:physiology*; D044462:Receptors, Proteinase-Activated / Q000037:antagonists & inhibitors / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D014655:Vascular Resistance / Q000187:drug effects / Q000235:genetics; D014661:Vasoconstriction / Q000187:drug effects / Q000235:genetics; D010975:Platelet Aggregation Inhibitors
C540445:E 5555; D007097:Imines; D007783:Lactones; D011725:Pyridines; D044463:Receptor, PAR-1; D044462:Receptors, Proteinase-Activated; C530299:vorapaxar; D010975:Platelet Aggregation Inhibitors